

Global End Stage Renal Disease Drug Market Growth 2026-2032

<https://marketpublishers.com/r/G8D8832DD9A8EN.html>

Date: April 2026

Pages: 134

Price: US\$ 3,660.00 (Single User License)

ID: G8D8832DD9A8EN

Abstracts

The global End Stage Renal Disease Drug market size is predicted to grow from US\$ million in 2025 to US\$ million in 2032; it is expected to grow at a CAGR of % from 2026 to 2032.

End-stage kidney disease drugs are used widely to treat end-stage kidney disease also known as the late stage renal disease, which occurs when chronic kidney disease reaches an advanced state. In this stage, the kidneys can no longer work, as they should to meet the body's needs. It damages the nephron and the kidney cannot function to remove the waste product from the body. The disease can cause other severe problems such as kidney failure, hypertension, brain aneurysm, and chronic pain.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive

to emerging public health needs.

LP Information, Inc. (LPI) ' newest research report, the 'End Stage Renal Disease Drug Industry Forecast' looks at past sales and reviews total world End Stage Renal Disease Drug sales in 2025, providing a comprehensive analysis by region and market sector of projected End Stage Renal Disease Drug sales for 2026 through 2032. With End Stage Renal Disease Drug sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US\$ millions of the world End Stage Renal Disease Drug industry.

This Insight Report provides a comprehensive analysis of the global End Stage Renal Disease Drug landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on End Stage Renal Disease Drug portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global End Stage Renal Disease Drug market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for End Stage Renal Disease Drug and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global End Stage Renal Disease Drug.

This report presents a comprehensive overview, market shares, and growth opportunities of End Stage Renal Disease Drug market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:

Calcimimetics

Vitamin D

Sterols

Potassium Binders

Calcium-Based Phosphate Binders

Other

Segmentation by Application:

End Stage Renal Disease Induced Hyperparathyroidism

End Stage Renal Disease Induced Hyperphosphatemia

End Stage Renal Disease Induced Hyperkalaemia

This report also splits the market by region:

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.

Pfizer Inc

AstraZeneca

Bristol-Myers Squibb Company

Dr. Reddy's Laboratories Ltd

Endo International plc

Teva Pharmaceutical Industries Ltd

Sun Pharmaceutical Industries Ltd

Mylan NV

Novartis AG

Lupin

Cipla Inc

Aurobindo Pharma

Fresenius SE & Co. KGaA

Sanofi

Takeda Pharmaceutical Company Limited

F. Hoffmann-La Roche Ltd

Kissei Pharmaceutical Co., Ltd

Abbott

Key Questions Addressed in this Report

What is the 10-year outlook for the global End Stage Renal Disease Drug market?

What factors are driving End Stage Renal Disease Drug market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do End Stage Renal Disease Drug market opportunities vary by end market size?

How does End Stage Renal Disease Drug break out by Type, by Application?

Contents

1 SCOPE OF THE REPORT

- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
- 1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

2.1 World Market Overview

- 2.1.1 Global End Stage Renal Disease Drug Annual Sales 2021-2032
- 2.1.2 World Current & Future Analysis for End Stage Renal Disease Drug by Geographic Region, 2021, 2025 & 2032
- 2.1.3 World Current & Future Analysis for End Stage Renal Disease Drug by Country/Region, 2021, 2025 & 2032

2.2 End Stage Renal Disease Drug Segment by Type

- 2.2.1 Calcimimetics
- 2.2.2 Vitamin D
- 2.2.3 Sterols
- 2.2.4 Potassium Binders
- 2.2.5 Calcium-Based Phosphate Binders
- 2.2.6 Other
- 2.2.7 End Stage Renal Disease Drug Sales by Type
 - 2.2.7.1 Global End Stage Renal Disease Drug Sales Market Share by Type (2021-2026)
 - 2.2.7.2 Global End Stage Renal Disease Drug Revenue and Market Share by Type (2021-2026)
 - 2.2.7.3 Global End Stage Renal Disease Drug Sale Price by Type (2021-2026)

2.3 End Stage Renal Disease Drug Segment by Application

- 2.3.1 End Stage Renal Disease Induced Hyperparathyroidism
- 2.3.2 End Stage Renal Disease Induced Hyperphosphatemia
- 2.3.3 End Stage Renal Disease Induced Hyperkalaemia
- 2.3.4 End Stage Renal Disease Drug Sales by Application

2.3.4.1 Global End Stage Renal Disease Drug Sale Market Share by Application (2021-2026)

2.3.4.2 Global End Stage Renal Disease Drug Revenue and Market Share by Application (2021-2026)

2.3.4.3 Global End Stage Renal Disease Drug Sale Price by Application (2021-2026)

3 GLOBAL BY COMPANY

3.1 Global End Stage Renal Disease Drug Breakdown Data by Company

3.1.1 Global End Stage Renal Disease Drug Annual Sales by Company (2021-2026)

3.1.2 Global End Stage Renal Disease Drug Sales Market Share by Company (2021-2026)

3.2 Global End Stage Renal Disease Drug Annual Revenue by Company (2021-2026)

3.2.1 Global End Stage Renal Disease Drug Revenue by Company (2021-2026)

3.2.2 Global End Stage Renal Disease Drug Revenue Market Share by Company (2021-2026)

3.3 Global End Stage Renal Disease Drug Sale Price by Company

3.4 Key Manufacturers End Stage Renal Disease Drug Producing Area Distribution, Sales Area, Product Type

3.4.1 Key Manufacturers End Stage Renal Disease Drug Product Location Distribution

3.4.2 Players End Stage Renal Disease Drug Products Offered

3.5 Market Concentration Rate Analysis

3.5.1 Competition Landscape Analysis

3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)

3.6 New Products and Potential Entrants

3.7 Market M&A Activity & Strategy

4 WORLD HISTORIC REVIEW FOR END STAGE RENAL DISEASE DRUG BY GEOGRAPHIC REGION

4.1 World Historic End Stage Renal Disease Drug Market Size by Geographic Region (2021-2026)

4.1.1 Global End Stage Renal Disease Drug Annual Sales by Geographic Region (2021-2026)

4.1.2 Global End Stage Renal Disease Drug Annual Revenue by Geographic Region (2021-2026)

4.2 World Historic End Stage Renal Disease Drug Market Size by Country/Region (2021-2026)

4.2.1 Global End Stage Renal Disease Drug Annual Sales by Country/Region

(2021-2026)

4.2.2 Global End Stage Renal Disease Drug Annual Revenue by Country/Region

(2021-2026)

4.3 Americas End Stage Renal Disease Drug Sales Growth

4.4 APAC End Stage Renal Disease Drug Sales Growth

4.5 Europe End Stage Renal Disease Drug Sales Growth

4.6 Middle East & Africa End Stage Renal Disease Drug Sales Growth

5 AMERICAS

5.1 Americas End Stage Renal Disease Drug Sales by Country

5.1.1 Americas End Stage Renal Disease Drug Sales by Country (2021-2026)

5.1.2 Americas End Stage Renal Disease Drug Revenue by Country (2021-2026)

5.2 Americas End Stage Renal Disease Drug Sales by Type (2021-2026)

5.3 Americas End Stage Renal Disease Drug Sales by Application (2021-2026)

5.4 United States

5.5 Canada

5.6 Mexico

5.7 Brazil

6 APAC

6.1 APAC End Stage Renal Disease Drug Sales by Region

6.1.1 APAC End Stage Renal Disease Drug Sales by Region (2021-2026)

6.1.2 APAC End Stage Renal Disease Drug Revenue by Region (2021-2026)

6.2 APAC End Stage Renal Disease Drug Sales by Type (2021-2026)

6.3 APAC End Stage Renal Disease Drug Sales by Application (2021-2026)

6.4 China

6.5 Japan

6.6 South Korea

6.7 Southeast Asia

6.8 India

6.9 Australia

6.10 China Taiwan

7 EUROPE

7.1 Europe End Stage Renal Disease Drug by Country

7.1.1 Europe End Stage Renal Disease Drug Sales by Country (2021-2026)

- 7.1.2 Europe End Stage Renal Disease Drug Revenue by Country (2021-2026)
- 7.2 Europe End Stage Renal Disease Drug Sales by Type (2021-2026)
- 7.3 Europe End Stage Renal Disease Drug Sales by Application (2021-2026)
- 7.4 Germany
- 7.5 France
- 7.6 UK
- 7.7 Italy
- 7.8 Russia

8 MIDDLE EAST & AFRICA

- 8.1 Middle East & Africa End Stage Renal Disease Drug by Country
 - 8.1.1 Middle East & Africa End Stage Renal Disease Drug Sales by Country (2021-2026)
 - 8.1.2 Middle East & Africa End Stage Renal Disease Drug Revenue by Country (2021-2026)
- 8.2 Middle East & Africa End Stage Renal Disease Drug Sales by Type (2021-2026)
- 8.3 Middle East & Africa End Stage Renal Disease Drug Sales by Application (2021-2026)
- 8.4 Egypt
- 8.5 South Africa
- 8.6 Israel
- 8.7 Turkey
- 8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

- 9.1 Market Drivers & Growth Opportunities
- 9.2 Market Challenges & Risks
- 9.3 Industry Trends

10 MANUFACTURING COST STRUCTURE ANALYSIS

- 10.1 Raw Material and Suppliers
- 10.2 Manufacturing Cost Structure Analysis of End Stage Renal Disease Drug
- 10.3 Manufacturing Process Analysis of End Stage Renal Disease Drug
- 10.4 Industry Chain Structure of End Stage Renal Disease Drug

11 MARKETING, DISTRIBUTORS AND CUSTOMER

11.1 Sales Channel

11.1.1 Direct Channels

11.1.2 Indirect Channels

11.2 End Stage Renal Disease Drug Distributors

11.3 End Stage Renal Disease Drug Customer

12 WORLD FORECAST REVIEW FOR END STAGE RENAL DISEASE DRUG BY GEOGRAPHIC REGION

12.1 Global End Stage Renal Disease Drug Market Size Forecast by Region

12.1.1 Global End Stage Renal Disease Drug Forecast by Region (2027-2032)

12.1.2 Global End Stage Renal Disease Drug Annual Revenue Forecast by Region (2027-2032)

12.2 Americas Forecast by Country (2027-2032)

12.3 APAC Forecast by Region (2027-2032)

12.4 Europe Forecast by Country (2027-2032)

12.5 Middle East & Africa Forecast by Country (2027-2032)

12.6 Global End Stage Renal Disease Drug Forecast by Type (2027-2032)

12.7 Global End Stage Renal Disease Drug Forecast by Application (2027-2032)

13 KEY PLAYERS ANALYSIS

13.1 Pfizer Inc

13.1.1 Pfizer Inc Company Information

13.1.2 Pfizer Inc End Stage Renal Disease Drug Product Portfolios and Specifications

13.1.3 Pfizer Inc End Stage Renal Disease Drug Sales, Revenue, Price and Gross Margin (2021-2026)

13.1.4 Pfizer Inc Main Business Overview

13.1.5 Pfizer Inc Latest Developments

13.2 AstraZeneca

13.2.1 AstraZeneca Company Information

13.2.2 AstraZeneca End Stage Renal Disease Drug Product Portfolios and Specifications

13.2.3 AstraZeneca End Stage Renal Disease Drug Sales, Revenue, Price and Gross Margin (2021-2026)

13.2.4 AstraZeneca Main Business Overview

13.2.5 AstraZeneca Latest Developments

13.3 Bristol-Myers Squibb Company

- 13.3.1 Bristol-Myers Squibb Company Company Information
- 13.3.2 Bristol-Myers Squibb Company End Stage Renal Disease Drug Product Portfolios and Specifications
- 13.3.3 Bristol-Myers Squibb Company End Stage Renal Disease Drug Sales, Revenue, Price and Gross Margin (2021-2026)
- 13.3.4 Bristol-Myers Squibb Company Main Business Overview
- 13.3.5 Bristol-Myers Squibb Company Latest Developments
- 13.4 Dr. Reddy's Laboratories Ltd
 - 13.4.1 Dr. Reddy's Laboratories Ltd Company Information
 - 13.4.2 Dr. Reddy's Laboratories Ltd End Stage Renal Disease Drug Product Portfolios and Specifications
 - 13.4.3 Dr. Reddy's Laboratories Ltd End Stage Renal Disease Drug Sales, Revenue, Price and Gross Margin (2021-2026)
 - 13.4.4 Dr. Reddy's Laboratories Ltd Main Business Overview
 - 13.4.5 Dr. Reddy's Laboratories Ltd Latest Developments
- 13.5 Endo International plc
 - 13.5.1 Endo International plc Company Information
 - 13.5.2 Endo International plc End Stage Renal Disease Drug Product Portfolios and Specifications
 - 13.5.3 Endo International plc End Stage Renal Disease Drug Sales, Revenue, Price and Gross Margin (2021-2026)
 - 13.5.4 Endo International plc Main Business Overview
 - 13.5.5 Endo International plc Latest Developments
- 13.6 Teva Pharmaceutical Industries Ltd
 - 13.6.1 Teva Pharmaceutical Industries Ltd Company Information
 - 13.6.2 Teva Pharmaceutical Industries Ltd End Stage Renal Disease Drug Product Portfolios and Specifications
 - 13.6.3 Teva Pharmaceutical Industries Ltd End Stage Renal Disease Drug Sales, Revenue, Price and Gross Margin (2021-2026)
 - 13.6.4 Teva Pharmaceutical Industries Ltd Main Business Overview
 - 13.6.5 Teva Pharmaceutical Industries Ltd Latest Developments
- 13.7 Sun Pharmaceutical Industries Ltd
 - 13.7.1 Sun Pharmaceutical Industries Ltd Company Information
 - 13.7.2 Sun Pharmaceutical Industries Ltd End Stage Renal Disease Drug Product Portfolios and Specifications
 - 13.7.3 Sun Pharmaceutical Industries Ltd End Stage Renal Disease Drug Sales, Revenue, Price and Gross Margin (2021-2026)
 - 13.7.4 Sun Pharmaceutical Industries Ltd Main Business Overview
 - 13.7.5 Sun Pharmaceutical Industries Ltd Latest Developments

13.8 Mylan NV

13.8.1 Mylan NV Company Information

13.8.2 Mylan NV End Stage Renal Disease Drug Product Portfolios and Specifications

13.8.3 Mylan NV End Stage Renal Disease Drug Sales, Revenue, Price and Gross Margin (2021-2026)

13.8.4 Mylan NV Main Business Overview

13.8.5 Mylan NV Latest Developments

13.9 Novartis AG

13.9.1 Novartis AG Company Information

13.9.2 Novartis AG End Stage Renal Disease Drug Product Portfolios and Specifications

13.9.3 Novartis AG End Stage Renal Disease Drug Sales, Revenue, Price and Gross Margin (2021-2026)

13.9.4 Novartis AG Main Business Overview

13.9.5 Novartis AG Latest Developments

13.10 Lupin

13.10.1 Lupin Company Information

13.10.2 Lupin End Stage Renal Disease Drug Product Portfolios and Specifications

13.10.3 Lupin End Stage Renal Disease Drug Sales, Revenue, Price and Gross Margin (2021-2026)

13.10.4 Lupin Main Business Overview

13.10.5 Lupin Latest Developments

13.11 Cipla Inc

13.11.1 Cipla Inc Company Information

13.11.2 Cipla Inc End Stage Renal Disease Drug Product Portfolios and Specifications

13.11.3 Cipla Inc End Stage Renal Disease Drug Sales, Revenue, Price and Gross Margin (2021-2026)

13.11.4 Cipla Inc Main Business Overview

13.11.5 Cipla Inc Latest Developments

13.12 Aurobindo Pharma

13.12.1 Aurobindo Pharma Company Information

13.12.2 Aurobindo Pharma End Stage Renal Disease Drug Product Portfolios and Specifications

13.12.3 Aurobindo Pharma End Stage Renal Disease Drug Sales, Revenue, Price and Gross Margin (2021-2026)

13.12.4 Aurobindo Pharma Main Business Overview

13.12.5 Aurobindo Pharma Latest Developments

13.13 Fresenius SE & Co. KGaA

13.13.1 Fresenius SE & Co. KGaA Company Information

13.13.2 Fresenius SE & Co. KGaA End Stage Renal Disease Drug Product Portfolios and Specifications

13.13.3 Fresenius SE & Co. KGaA End Stage Renal Disease Drug Sales, Revenue, Price and Gross Margin (2021-2026)

13.13.4 Fresenius SE & Co. KGaA Main Business Overview

13.13.5 Fresenius SE & Co. KGaA Latest Developments

13.14 Sanofi

13.14.1 Sanofi Company Information

13.14.2 Sanofi End Stage Renal Disease Drug Product Portfolios and Specifications

13.14.3 Sanofi End Stage Renal Disease Drug Sales, Revenue, Price and Gross Margin (2021-2026)

13.14.4 Sanofi Main Business Overview

13.14.5 Sanofi Latest Developments

13.15 Takeda Pharmaceutical Company Limited

13.15.1 Takeda Pharmaceutical Company Limited Company Information

13.15.2 Takeda Pharmaceutical Company Limited End Stage Renal Disease Drug Product Portfolios and Specifications

13.15.3 Takeda Pharmaceutical Company Limited End Stage Renal Disease Drug Sales, Revenue, Price and Gross Margin (2021-2026)

13.15.4 Takeda Pharmaceutical Company Limited Main Business Overview

13.15.5 Takeda Pharmaceutical Company Limited Latest Developments

13.16 F. Hoffmann-La Roche Ltd

13.16.1 F. Hoffmann-La Roche Ltd Company Information

13.16.2 F. Hoffmann-La Roche Ltd End Stage Renal Disease Drug Product Portfolios and Specifications

13.16.3 F. Hoffmann-La Roche Ltd End Stage Renal Disease Drug Sales, Revenue, Price and Gross Margin (2021-2026)

13.16.4 F. Hoffmann-La Roche Ltd Main Business Overview

13.16.5 F. Hoffmann-La Roche Ltd Latest Developments

13.17 Kissei Pharmaceutical Co., Ltd

13.17.1 Kissei Pharmaceutical Co., Ltd Company Information

13.17.2 Kissei Pharmaceutical Co., Ltd End Stage Renal Disease Drug Product Portfolios and Specifications

13.17.3 Kissei Pharmaceutical Co., Ltd End Stage Renal Disease Drug Sales, Revenue, Price and Gross Margin (2021-2026)

13.17.4 Kissei Pharmaceutical Co., Ltd Main Business Overview

13.17.5 Kissei Pharmaceutical Co., Ltd Latest Developments

13.18 Abbott

13.18.1 Abbott Company Information

- 13.18.2 Abbott End Stage Renal Disease Drug Product Portfolios and Specifications
- 13.18.3 Abbott End Stage Renal Disease Drug Sales, Revenue, Price and Gross Margin (2021-2026)
- 13.18.4 Abbott Main Business Overview
- 13.18.5 Abbott Latest Developments

14 RESEARCH FINDINGS AND CONCLUSION

List Of Tables

LIST OF TABLES

Table 1. End Stage Renal Disease Drug Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & (\$ millions)

Table 2. End Stage Renal Disease Drug Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & (\$ millions)

Table 3. Major Players of Calcimimetics

Table 4. Major Players of Vitamin D

Table 5. Major Players of Sterols

Table 6. Major Players of Potassium Binders

Table 7. Major Players of Calcium-Based Phosphate Binders

Table 8. Major Players of Other

Table 9. Global End Stage Renal Disease Drug Sales by Type (2021-2026) & (K Units)

Table 10. Global End Stage Renal Disease Drug Sales Market Share by Type (2021-2026)

Table 11. Global End Stage Renal Disease Drug Revenue by Type (2021-2026) & (\$ million)

Table 12. Global End Stage Renal Disease Drug Revenue Market Share by Type (2021-2026)

Table 13. Global End Stage Renal Disease Drug Sale Price by Type (2021-2026) & (US\$/Unit)

Table 14. Global End Stage Renal Disease Drug Sale by Application (2021-2026) & (K Units)

Table 15. Global End Stage Renal Disease Drug Sale Market Share by Application (2021-2026)

Table 16. Global End Stage Renal Disease Drug Revenue by Application (2021-2026) & (\$ million)

Table 17. Global End Stage Renal Disease Drug Revenue Market Share by Application (2021-2026)

Table 18. Global End Stage Renal Disease Drug Sale Price by Application (2021-2026) & (US\$/Unit)

Table 19. Global End Stage Renal Disease Drug Sales by Company (2021-2026) & (K Units)

Table 20. Global End Stage Renal Disease Drug Sales Market Share by Company (2021-2026)

Table 21. Global End Stage Renal Disease Drug Revenue by Company (2021-2026) & (\$ millions)

Table 22. Global End Stage Renal Disease Drug Revenue Market Share by Company (2021-2026)

Table 23. Global End Stage Renal Disease Drug Sale Price by Company (2021-2026) & (US\$/Unit)

Table 24. Key Manufacturers End Stage Renal Disease Drug Producing Area Distribution and Sales Area

Table 25. Players End Stage Renal Disease Drug Products Offered

Table 26. End Stage Renal Disease Drug Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)

Table 27. New Products and Potential Entrants

Table 28. Market M&A Activity & Strategy

Table 29. Global End Stage Renal Disease Drug Sales by Geographic Region (2021-2026) & (K Units)

Table 30. Global End Stage Renal Disease Drug Sales Market Share Geographic Region (2021-2026)

Table 31. Global End Stage Renal Disease Drug Revenue by Geographic Region (2021-2026) & (\$ millions)

Table 32. Global End Stage Renal Disease Drug Revenue Market Share by Geographic Region (2021-2026)

Table 33. Global End Stage Renal Disease Drug Sales by Country/Region (2021-2026) & (K Units)

Table 34. Global End Stage Renal Disease Drug Sales Market Share by Country/Region (2021-2026)

Table 35. Global End Stage Renal Disease Drug Revenue by Country/Region (2021-2026) & (\$ millions)

Table 36. Global End Stage Renal Disease Drug Revenue Market Share by Country/Region (2021-2026)

Table 37. Americas End Stage Renal Disease Drug Sales by Country (2021-2026) & (K Units)

Table 38. Americas End Stage Renal Disease Drug Sales Market Share by Country (2021-2026)

Table 39. Americas End Stage Renal Disease Drug Revenue by Country (2021-2026) & (\$ millions)

Table 40. Americas End Stage Renal Disease Drug Sales by Type (2021-2026) & (K Units)

Table 41. Americas End Stage Renal Disease Drug Sales by Application (2021-2026) & (K Units)

Table 42. APAC End Stage Renal Disease Drug Sales by Region (2021-2026) & (K Units)

- Table 43. APAC End Stage Renal Disease Drug Sales Market Share by Region (2021-2026)
- Table 44. APAC End Stage Renal Disease Drug Revenue by Region (2021-2026) & (\$ millions)
- Table 45. APAC End Stage Renal Disease Drug Sales by Type (2021-2026) & (K Units)
- Table 46. APAC End Stage Renal Disease Drug Sales by Application (2021-2026) & (K Units)
- Table 47. Europe End Stage Renal Disease Drug Sales by Country (2021-2026) & (K Units)
- Table 48. Europe End Stage Renal Disease Drug Revenue by Country (2021-2026) & (\$ millions)
- Table 49. Europe End Stage Renal Disease Drug Sales by Type (2021-2026) & (K Units)
- Table 50. Europe End Stage Renal Disease Drug Sales by Application (2021-2026) & (K Units)
- Table 51. Middle East & Africa End Stage Renal Disease Drug Sales by Country (2021-2026) & (K Units)
- Table 52. Middle East & Africa End Stage Renal Disease Drug Revenue Market Share by Country (2021-2026)
- Table 53. Middle East & Africa End Stage Renal Disease Drug Sales by Type (2021-2026) & (K Units)
- Table 54. Middle East & Africa End Stage Renal Disease Drug Sales by Application (2021-2026) & (K Units)
- Table 55. Key Market Drivers & Growth Opportunities of End Stage Renal Disease Drug
- Table 56. Key Market Challenges & Risks of End Stage Renal Disease Drug
- Table 57. Key Industry Trends of End Stage Renal Disease Drug
- Table 58. End Stage Renal Disease Drug Raw Material
- Table 59. Key Suppliers of Raw Materials
- Table 60. End Stage Renal Disease Drug Distributors List
- Table 61. End Stage Renal Disease Drug Customer List
- Table 62. Global End Stage Renal Disease Drug Sales Forecast by Region (2027-2032) & (K Units)
- Table 63. Global End Stage Renal Disease Drug Revenue Forecast by Region (2027-2032) & (\$ millions)
- Table 64. Americas End Stage Renal Disease Drug Sales Forecast by Country (2027-2032) & (K Units)
- Table 65. Americas End Stage Renal Disease Drug Annual Revenue Forecast by Country (2027-2032) & (\$ millions)
- Table 66. APAC End Stage Renal Disease Drug Sales Forecast by Region (2027-2032)

& (K Units)

Table 67. APAC End Stage Renal Disease Drug Annual Revenue Forecast by Region (2027-2032) & (\$ millions)

Table 68. Europe End Stage Renal Disease Drug Sales Forecast by Country (2027-2032) & (K Units)

Table 69. Europe End Stage Renal Disease Drug Revenue Forecast by Country (2027-2032) & (\$ millions)

Table 70. Middle East & Africa End Stage Renal Disease Drug Sales Forecast by Country (2027-2032) & (K Units)

Table 71. Middle East & Africa End Stage Renal Disease Drug Revenue Forecast by Country (2027-2032) & (\$ millions)

Table 72. Global End Stage Renal Disease Drug Sales Forecast by Type (2027-2032) & (K Units)

Table 73. Global End Stage Renal Disease Drug Revenue Forecast by Type (2027-2032) & (\$ millions)

Table 74. Global End Stage Renal Disease Drug Sales Forecast by Application (2027-2032) & (K Units)

Table 75. Global End Stage Renal Disease Drug Revenue Forecast by Application (2027-2032) & (\$ millions)

Table 76. Pfizer Inc Basic Information, End Stage Renal Disease Drug Manufacturing Base, Sales Area and Its Competitors

Table 77. Pfizer Inc End Stage Renal Disease Drug Product Portfolios and Specifications

Table 78. Pfizer Inc End Stage Renal Disease Drug Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 79. Pfizer Inc Main Business

Table 80. Pfizer Inc Latest Developments

Table 81. AstraZeneca Basic Information, End Stage Renal Disease Drug Manufacturing Base, Sales Area and Its Competitors

Table 82. AstraZeneca End Stage Renal Disease Drug Product Portfolios and Specifications

Table 83. AstraZeneca End Stage Renal Disease Drug Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 84. AstraZeneca Main Business

Table 85. AstraZeneca Latest Developments

Table 86. Bristol-Myers Squibb Company Basic Information, End Stage Renal Disease Drug Manufacturing Base, Sales Area and Its Competitors

Table 87. Bristol-Myers Squibb Company End Stage Renal Disease Drug Product Portfolios and Specifications

Table 88. Bristol-Myers Squibb Company End Stage Renal Disease Drug Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 89. Bristol-Myers Squibb Company Main Business

Table 90. Bristol-Myers Squibb Company Latest Developments

Table 91. Dr. Reddy's Laboratories Ltd Basic Information, End Stage Renal Disease Drug Manufacturing Base, Sales Area and Its Competitors

Table 92. Dr. Reddy's Laboratories Ltd End Stage Renal Disease Drug Product Portfolios and Specifications

Table 93. Dr. Reddy's Laboratories Ltd End Stage Renal Disease Drug Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 94. Dr. Reddy's Laboratories Ltd Main Business

Table 95. Dr. Reddy's Laboratories Ltd Latest Developments

Table 96. Endo International plc Basic Information, End Stage Renal Disease Drug Manufacturing Base, Sales Area and Its Competitors

Table 97. Endo International plc End Stage Renal Disease Drug Product Portfolios and Specifications

Table 98. Endo International plc End Stage Renal Disease Drug Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 99. Endo International plc Main Business

Table 100. Endo International plc Latest Developments

Table 101. Teva Pharmaceutical Industries Ltd Basic Information, End Stage Renal Disease Drug Manufacturing Base, Sales Area and Its Competitors

Table 102. Teva Pharmaceutical Industries Ltd End Stage Renal Disease Drug Product Portfolios and Specifications

Table 103. Teva Pharmaceutical Industries Ltd End Stage Renal Disease Drug Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 104. Teva Pharmaceutical Industries Ltd Main Business

Table 105. Teva Pharmaceutical Industries Ltd Latest Developments

Table 106. Sun Pharmaceutical Industries Ltd Basic Information, End Stage Renal Disease Drug Manufacturing Base, Sales Area and Its Competitors

Table 107. Sun Pharmaceutical Industries Ltd End Stage Renal Disease Drug Product Portfolios and Specifications

Table 108. Sun Pharmaceutical Industries Ltd End Stage Renal Disease Drug Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 109. Sun Pharmaceutical Industries Ltd Main Business

Table 110. Sun Pharmaceutical Industries Ltd Latest Developments

Table 111. Mylan NV Basic Information, End Stage Renal Disease Drug Manufacturing Base, Sales Area and Its Competitors

Table 112. Mylan NV End Stage Renal Disease Drug Product Portfolios and

Specifications

Table 113. Mylan NV End Stage Renal Disease Drug Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 114. Mylan NV Main Business

Table 115. Mylan NV Latest Developments

Table 116. Novartis AG Basic Information, End Stage Renal Disease Drug Manufacturing Base, Sales Area and Its Competitors

Table 117. Novartis AG End Stage Renal Disease Drug Product Portfolios and Specifications

Table 118. Novartis AG End Stage Renal Disease Drug Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 119. Novartis AG Main Business

Table 120. Novartis AG Latest Developments

Table 121. Lupin Basic Information, End Stage Renal Disease Drug Manufacturing Base, Sales Area and Its Competitors

Table 122. Lupin End Stage Renal Disease Drug Product Portfolios and Specifications

Table 123. Lupin End Stage Renal Disease Drug Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 124. Lupin Main Business

Table 125. Lupin Latest Developments

Table 126. Cipla Inc Basic Information, End Stage Renal Disease Drug Manufacturing Base, Sales Area and Its Competitors

Table 127. Cipla Inc End Stage Renal Disease Drug Product Portfolios and Specifications

Table 128. Cipla Inc End Stage Renal Disease Drug Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 129. Cipla Inc Main Business

Table 130. Cipla Inc Latest Developments

Table 131. Aurobindo Pharma Basic Information, End Stage Renal Disease Drug Manufacturing Base, Sales Area and Its Competitors

Table 132. Aurobindo Pharma End Stage Renal Disease Drug Product Portfolios and Specifications

Table 133. Aurobindo Pharma End Stage Renal Disease Drug Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 134. Aurobindo Pharma Main Business

Table 135. Aurobindo Pharma Latest Developments

Table 136. Fresenius SE & Co. KGaA Basic Information, End Stage Renal Disease Drug Manufacturing Base, Sales Area and Its Competitors

Table 137. Fresenius SE & Co. KGaA End Stage Renal Disease Drug Product

Portfolios and Specifications

Table 138. Fresenius SE & Co. KGaA End Stage Renal Disease Drug Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 139. Fresenius SE & Co. KGaA Main Business

Table 140. Fresenius SE & Co. KGaA Latest Developments

Table 141. Sanofi Basic Information, End Stage Renal Disease Drug Manufacturing Base, Sales Area and Its Competitors

Table 142. Sanofi End Stage Renal Disease Drug Product Portfolios and Specifications

Table 143. Sanofi End Stage Renal Disease Drug Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 144. Sanofi Main Business

Table 145. Sanofi Latest Developments

Table 146. Takeda Pharmaceutical Company Limited Basic Information, End Stage Renal Disease Drug Manufacturing Base, Sales Area and Its Competitors

Table 147. Takeda Pharmaceutical Company Limited End Stage Renal Disease Drug Product Portfolios and Specifications

Table 148. Takeda Pharmaceutical Company Limited End Stage Renal Disease Drug Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 149. Takeda Pharmaceutical Company Limited Main Business

Table 150. Takeda Pharmaceutical Company Limited Latest Developments

Table 151. F. Hoffmann-La Roche Ltd Basic Information, End Stage Renal Disease Drug Manufacturing Base, Sales Area and Its Competitors

Table 152. F. Hoffmann-La Roche Ltd End Stage Renal Disease Drug Product Portfolios and Specifications

Table 153. F. Hoffmann-La Roche Ltd End Stage Renal Disease Drug Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 154. F. Hoffmann-La Roche Ltd Main Business

Table 155. F. Hoffmann-La Roche Ltd Latest Developments

Table 156. Kissei Pharmaceutical Co., Ltd Basic Information, End Stage Renal Disease Drug Manufacturing Base, Sales Area and Its Competitors

Table 157. Kissei Pharmaceutical Co., Ltd End Stage Renal Disease Drug Product Portfolios and Specifications

Table 158. Kissei Pharmaceutical Co., Ltd End Stage Renal Disease Drug Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 159. Kissei Pharmaceutical Co., Ltd Main Business

Table 160. Kissei Pharmaceutical Co., Ltd Latest Developments

Table 161. Abbott Basic Information, End Stage Renal Disease Drug Manufacturing Base, Sales Area and Its Competitors

Table 162. Abbott End Stage Renal Disease Drug Product Portfolios and Specifications

Table 163. Abbott End Stage Renal Disease Drug Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 164. Abbott Main Business

Table 165. Abbott Latest Developments

List Of Figures

LIST OF FIGURES

- Figure 1. Picture of End Stage Renal Disease Drug
- Figure 2. End Stage Renal Disease Drug Report Years Considered
- Figure 3. Research Objectives
- Figure 4. Research Methodology
- Figure 5. Research Process and Data Source
- Figure 6. Global End Stage Renal Disease Drug Sales Growth Rate 2021-2032 (K Units)
- Figure 7. Global End Stage Renal Disease Drug Revenue Growth Rate 2021-2032 (\$ millions)
- Figure 8. End Stage Renal Disease Drug Sales by Geographic Region (2021, 2025 & 2032) & (\$ millions)
- Figure 9. End Stage Renal Disease Drug Sales Market Share by Country/Region (2025)
- Figure 10. End Stage Renal Disease Drug Sales Market Share by Country/Region (2021, 2025 & 2032)
- Figure 11. Product Picture of Calcimimetics
- Figure 12. Product Picture of Vitamin D
- Figure 13. Product Picture of Sterols
- Figure 14. Product Picture of Potassium Binders
- Figure 15. Product Picture of Calcium-Based Phosphate Binders
- Figure 16. Product Picture of Other
- Figure 17. Global End Stage Renal Disease Drug Sales Market Share by Type in 2026
- Figure 18. Global End Stage Renal Disease Drug Revenue Market Share by Type (2021-2026)
- Figure 19. End Stage Renal Disease Drug Consumed in End Stage Renal Disease Induced Hyperparathyroidism
- Figure 20. Global End Stage Renal Disease Drug Market: End Stage Renal Disease Induced Hyperparathyroidism (2021-2026) & (K Units)
- Figure 21. End Stage Renal Disease Drug Consumed in End Stage Renal Disease Induced Hyperphosphatemia
- Figure 22. Global End Stage Renal Disease Drug Market: End Stage Renal Disease Induced Hyperphosphatemia (2021-2026) & (K Units)
- Figure 23. End Stage Renal Disease Drug Consumed in End Stage Renal Disease Induced Hyperkalaemia
- Figure 24. Global End Stage Renal Disease Drug Market: End Stage Renal Disease Induced Hyperkalaemia (2021-2026) & (K Units)

Figure 25. Global End Stage Renal Disease Drug Sale Market Share by Application (2025)

Figure 26. Global End Stage Renal Disease Drug Revenue Market Share by Application in 2026

Figure 27. End Stage Renal Disease Drug Sales by Company in 2026 (K Units)

Figure 28. Global End Stage Renal Disease Drug Sales Market Share by Company in 2026

Figure 29. End Stage Renal Disease Drug Revenue by Company in 2026 (\$ millions)

Figure 30. Global End Stage Renal Disease Drug Revenue Market Share by Company in 2026

Figure 31. Global End Stage Renal Disease Drug Sales Market Share by Geographic Region (2021-2026)

Figure 32. Global End Stage Renal Disease Drug Revenue Market Share by Geographic Region in 2026

Figure 33. Americas End Stage Renal Disease Drug Sales 2021-2026 (K Units)

Figure 34. Americas End Stage Renal Disease Drug Revenue 2021-2026 (\$ millions)

Figure 35. APAC End Stage Renal Disease Drug Sales 2021-2026 (K Units)

Figure 36. APAC End Stage Renal Disease Drug Revenue 2021-2026 (\$ millions)

Figure 37. Europe End Stage Renal Disease Drug Sales 2021-2026 (K Units)

Figure 38. Europe End Stage Renal Disease Drug Revenue 2021-2026 (\$ millions)

Figure 39. Middle East & Africa End Stage Renal Disease Drug Sales 2021-2026 (K Units)

Figure 40. Middle East & Africa End Stage Renal Disease Drug Revenue 2021-2026 (\$ millions)

Figure 41. Americas End Stage Renal Disease Drug Sales Market Share by Country in 2026

Figure 42. Americas End Stage Renal Disease Drug Revenue Market Share by Country (2021-2026)

Figure 43. Americas End Stage Renal Disease Drug Sales Market Share by Type (2021-2026)

Figure 44. Americas End Stage Renal Disease Drug Sales Market Share by Application (2021-2026)

Figure 45. United States End Stage Renal Disease Drug Revenue Growth 2021-2026 (\$ millions)

Figure 46. Canada End Stage Renal Disease Drug Revenue Growth 2021-2026 (\$ millions)

Figure 47. Mexico End Stage Renal Disease Drug Revenue Growth 2021-2026 (\$ millions)

Figure 48. Brazil End Stage Renal Disease Drug Revenue Growth 2021-2026 (\$

millions)

Figure 49. APAC End Stage Renal Disease Drug Sales Market Share by Region in 2026

Figure 50. APAC End Stage Renal Disease Drug Revenue Market Share by Region (2021-2026)

Figure 51. APAC End Stage Renal Disease Drug Sales Market Share by Type (2021-2026)

Figure 52. APAC End Stage Renal Disease Drug Sales Market Share by Application (2021-2026)

Figure 53. China End Stage Renal Disease Drug Revenue Growth 2021-2026 (\$ millions)

Figure 54. Japan End Stage Renal Disease Drug Revenue Growth 2021-2026 (\$ millions)

Figure 55. South Korea End Stage Renal Disease Drug Revenue Growth 2021-2026 (\$ millions)

Figure 56. Southeast Asia End Stage Renal Disease Drug Revenue Growth 2021-2026 (\$ millions)

Figure 57. India End Stage Renal Disease Drug Revenue Growth 2021-2026 (\$ millions)

Figure 58. Australia End Stage Renal Disease Drug Revenue Growth 2021-2026 (\$ millions)

Figure 59. China Taiwan End Stage Renal Disease Drug Revenue Growth 2021-2026 (\$ millions)

Figure 60. Europe End Stage Renal Disease Drug Sales Market Share by Country in 2026

Figure 61. Europe End Stage Renal Disease Drug Revenue Market Share by Country (2021-2026)

Figure 62. Europe End Stage Renal Disease Drug Sales Market Share by Type (2021-2026)

Figure 63. Europe End Stage Renal Disease Drug Sales Market Share by Application (2021-2026)

Figure 64. Germany End Stage Renal Disease Drug Revenue Growth 2021-2026 (\$ millions)

Figure 65. France End Stage Renal Disease Drug Revenue Growth 2021-2026 (\$ millions)

Figure 66. UK End Stage Renal Disease Drug Revenue Growth 2021-2026 (\$ millions)

Figure 67. Italy End Stage Renal Disease Drug Revenue Growth 2021-2026 (\$ millions)

Figure 68. Russia End Stage Renal Disease Drug Revenue Growth 2021-2026 (\$ millions)

- Figure 69. Middle East & Africa End Stage Renal Disease Drug Sales Market Share by Country (2021-2026)
- Figure 70. Middle East & Africa End Stage Renal Disease Drug Sales Market Share by Type (2021-2026)
- Figure 71. Middle East & Africa End Stage Renal Disease Drug Sales Market Share by Application (2021-2026)
- Figure 72. Egypt End Stage Renal Disease Drug Revenue Growth 2021-2026 (\$ millions)
- Figure 73. South Africa End Stage Renal Disease Drug Revenue Growth 2021-2026 (\$ millions)
- Figure 74. Israel End Stage Renal Disease Drug Revenue Growth 2021-2026 (\$ millions)
- Figure 75. Turkey End Stage Renal Disease Drug Revenue Growth 2021-2026 (\$ millions)
- Figure 76. GCC Countries End Stage Renal Disease Drug Revenue Growth 2021-2026 (\$ millions)
- Figure 77. Manufacturing Cost Structure Analysis of End Stage Renal Disease Drug in 2026
- Figure 78. Manufacturing Process Analysis of End Stage Renal Disease Drug
- Figure 79. Industry Chain Structure of End Stage Renal Disease Drug
- Figure 80. Channels of Distribution
- Figure 81. Global End Stage Renal Disease Drug Sales Market Forecast by Region (2027-2032)
- Figure 82. Global End Stage Renal Disease Drug Revenue Market Share Forecast by Region (2027-2032)
- Figure 83. Global End Stage Renal Disease Drug Sales Market Share Forecast by Type (2027-2032)
- Figure 84. Global End Stage Renal Disease Drug Revenue Market Share Forecast by Type (2027-2032)
- Figure 85. Global End Stage Renal Disease Drug Sales Market Share Forecast by Application (2027-2032)
- Figure 86. Global End Stage Renal Disease Drug Revenue Market Share Forecast by Application (2027-2032)

I would like to order

Product name: Global End Stage Renal Disease Drug Market Growth 2026-2032

Product link: <https://marketpublishers.com/r/G8D8832DD9A8EN.html>

Price: US\$ 3,660.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G8D8832DD9A8EN.html>